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Interleukin-17–Producing T Cells Are Enriched in the Joints of
Children With Arthritis, but Have a Reciprocal Relationship to
Regulatory T Cell Numbers
Kiran Nistala, Halima Moncrieffe, Katy R. Newton, Hemlata Varsani, Patricia Hunter,
and Lucy R. Wedderburn
Objective. To identify interleukin-17 (IL-17)–
producing T cells from patients with juvenile idiopathic
arthritis (JIA), and investigate their cytokine produc-
tion, migratory capacity, and relationship to Treg cells
at sites of inflammation, as well as to test the hypothesis
that IL-17 T cell numbers correlate with clinical
phenotype in childhood arthritis.
Methods. Flow cytometry was used to analyze the
phenotype, cytokine production, and chemokine recep-
tor expression of IL-17–producing T cells in peripheral
blood and synovial fluid mononuclear cells from 36
children with JIA, in parallel with analysis of forkhead
box P3 (FoxP3)–positive Treg cells. Migration of IL-17
T cells toward CCL20 was assessed by a Transwell
assay. Synovial tissue was analyzed by immunohisto-
chemistry for IL-17 and IL-22.
Results. IL-17 T cells were enriched in the joints
of children with JIA as compared with the blood of JIA
patients (P  0.0001) and controls (P  0.018) and were
demonstrated in synovial tissue. IL-17 T cell numbers
were higher in patients with extended oligoarthritis, the
more severe subtype of JIA, as compared with patients
with persistent oligoarthritis, the milder subtype (P 
0.046). Within the joint, there was an inverse relation-
ship between IL-17 T cells and FoxP3 Treg cells (r 
0.61, P  0.016). IL-17,CD4 T cells were uniformly
CCR6 and migrated toward CCL20, but synovial
IL-17 T cells had variable CCR4 expression. A pro-
portion of IL-17 synovial T cells produced IL-22 and
interferon-.
Conclusion. This study is the first to define the
frequency and characteristics of “Th17” cells in JIA.
We suggest that these highly proinflammatory cells
contribute to joint pathology, as indicated by relation-
ships with clinical phenotypes, and that the balance
between IL-17 T cells and Treg cells may be critical to
outcome.
Human autoimmune diseases, including inflam-
matory arthritis in both adults and children, have been
previously associated with a Th1 polarized response at
the site of inflammation (1–3). A new subset of effector
T cells that produce interleukin-17 (IL-17) has recently
been characterized (4–6). In mice, these Th17 cells
appear to be driven by the transcription factor retinoic
acid–related orphan receptor t (RORt) and to be
developmentally and functionally distinct from
interferon- (IFN)–producing type 1 (Th1) and IL-4–
producing type 2 (Th2) helper T cells (7–9). Aberrant
Th17 cell responses have been linked with autoimmune
disease in several animal models, including collagen-
induced arthritis and experimental autoimmune enceph-
alomyelitis, and it has been increasingly proposed that
Th17 cells, rather than Th1 cells, may be central to
disease pathogenesis (10,11).
The differentiation of murine Th17 cells from
naive T cells appears to require transforming growth
factor  (TGF) and IL-6 (8). Thus, the conditions for
generating these potent effector cells are related to
those required to generate regulatory T cells, namely,
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875TGF alone, whereas IL-6 and possibly other inflamma-
tory cytokines can provide the key switch from genera-
tion of Treg cells to Th17 cells (12). The requirements
for the generation of human Th17 cells in the physio-
logic context may be more dependent on IL-6 and IL-1
(13,14), but what regulates the balance between Th17
cells and Treg cells in health or disease has not yet been
fully elucidated.
The IL-17 family of cytokines, which includes the
T cell–derived proinflammatory cytokines IL-17A and
IL-17F, has been implicated in the pathogenesis of
rheumatoid arthritis (RA) and, more recently, juvenile
idiopathic arthritis (JIA). IL-17 is produced spontane-
ously by explanted synovial tissue from RA patients, has
been found at high levels in synovial fluid (15,16), and
has many downstream effects that mimic the pathology
of inflammatory arthritis. In JIA, IL-17 is increased in
patients with active disease as compared with those in
remission (17). IL-17 promotes a proinflammatory cyto-
kine milieu in the joint, stimulating the production of
IL-1 and tumor necrosis factor  (TNF) from macro-
phages (18), and synergizes with these to increase IL-6
and IL-8 production from RA synoviocytes (19,20), the
latter being important in neutrophil recruitment. IL-17
also promotes bone erosion through the up-regulation of
RANKL (15), a key regulator of osteoclast neogenesis.
RANKL has been demonstrated in high levels in JIA
(21,22) and RA (23,24). Downstream effects of IL-17
include production of metalloproteinases and proteogly-
can breakdown, leading to cartilage destruction (25,26).
Initial reports demonstrated Th17 cells in healthy
adults that express homing receptors and antigen spec-
ificities distinct from those of Th1 and Th2 cells (27). In
that study, a proportion of IL-17–producing T cells also
expressed IFN. T cells making both IL-17 and IFN
have also been observed in the synovial cells of RA
patients (28) and patients with Lyme arthritis (29).
However, the role and character of Th17 cells in human
arthritis and their relationship to Treg cells have not
been fully investigated to date.
JIA is a heterogeneous group of childhood ar-
thropathies (30) that offers a clinical paradigm by which
to examine the Treg cell–Th17 cell interplay at the site of
inflammation. We and other investigators have shown
that regulatory T cells are enriched in the synovial fluid
of JIA patients (31,32) and that these Treg cells are
present at significantly higher numbers in patients with a
milder clinical phenotype (persistent oligoarticular JIA)
than in those with a more severe form of arthritis
(extended oligoarticular JIA) (31). We have also shown
a marked enrichment of IFN-producing T cells that
express high levels of the chemokine receptors CCR5
and CXCR3 in the JIA joint (3) and that chemokines
(CCL5, CCL3, and CXCL10) that attract Th1 cells are
enriched in JIA synovial fluid (33). We have now
investigated whether Th17 cells can be demonstrated at
the site of inflammation in JIA and, if so, how they relate
to the Treg cell and Th1 cell populations, as well as to
the clinical disease phenotype.
The aims of this study were to identify and
characterize human IL-17–producing T cells from pa-
tients with JIA, the most common rheumatologic in-
flammatory autoimmune disease of childhood. We
tested the hypothesis that the numbers of IL-17 T cells
correlate with the clinical phenotype in childhood
arthritis. We explored the relationship between these
Th17 cells and FoxP3 Treg cells at sites of inflamma-
tion. We then investigated the production of other
cytokines by IL-17 T cells in JIA, in particular, IFN,
IL-4, and IL-22, their expression of chemokine recep-
tors, and their capacity to migrate to the CCR6 ligand
CCL20. We believe this to be the first study of IL-17
T cells and their relationship to FoxP3 Treg cells in
human arthritis.
PATIENTS AND METHODS
Patients and samples. Samples of peripheral blood
and synovial fluid from 36 children (28 females and 8 males)
who met the International League of Associations for Rheu-
matology criteria for JIA (30) and 11 healthy controls (7
females and 4 males) were included in the study. JIA pa-
tients had the following disease subtypes: 15 had persistent
oligoarthritis, 13 had extended oligoarthritis, 4 had systemic
onset, and 4 had polyarthritis. The mean age of the JIA
patients was 10.4 years (range 1.7–39 years), and the mean
disease duration was 5.3 years (range 0.2–18.6 years). Eleven
patients (31%) were receiving methotrexate, 22 (61%) were
receiving nonsteroidal antiinflammatory agents, and 2 (6%)
were receiving oral prednisolone at the time of sampling. All
patients attended the Great Ormond Street Hospital in Lon-
don. The study had approval from the local ethics review
committee. Full informed consent was obtained from the
parents of each child.
All patients had active disease at the time of sampling,
in that they required therapeutic joint aspiration and then
intraarticular injection of steroid. Synovial tissue samples (n 
3) were collected at the time of synovectomy or arthroplasty
and were snap frozen until further use. Paired samples of
peripheral blood and synovial fluid were obtained at the time
of clinically indicated arthrocentesis. Samples were processed
within 1 hour of collection from the patient. Peripheral blood
mononuclear cells (PBMCs) were isolated by standard Ficoll-
Hypaque density centrifugation. For preparation of synovial
fluid mononuclear cells (SFMCs), samples were first treated
876 NISTALA ET ALwith 10 units/ml of hyaluronidase (Sigma, Poole, UK) for 30
minutes at 37°C, before density gradient isolation.
For analysis of cytokine production by T cells, the
SFMCs or PBMCs were cultured for 3 hours in the presence of
50 ng/ml of phorbol myristate acetate (PMA), 500 ng/ml of
ionomycin, and 5 g/ml of Brefeldin A before analysis by
intracellular cytokine staining and flow cytometry, as described
elsewhere (3). For migration assays, purified CD4 T cells
were first prepared using magnetic beads (Miltenyi Biotec,
Surrey, UK) according to the manufacturer’s instructions.
Purity of the CD4 cells was always 92%.
Analysis by flow cytometry. Standard 5-color flow
cytometry was performed for surface markers using antibodies
against the following human proteins with fluorescent labels:
phycoerythrin (PE)–Cy7–labeled CD3 (SouthernBiotech, Bir-
mingham, AL), PE-labeled CD25 (Dako, Ely, UK), fluorescein
isothiocyanate (FITC)–labeled CD45RO (Serotec, Oxford,
UK), PE-labeled CD8 (Dako), and FITC-labeled T cell recep-
tor / (TCR/), peridinin chlorophyll A protein–labeled
CD4, PE-labeled CCR4, and PE-labeled CCR6 (all from BD
PharMingen, Oxford, UK).
For intracellular staining with antibodies against PE-
labeled human IL-4, FITC-labeled IFN (both from BD
PharMingen), Alexa Fluor 647–labeled IL-17A (eBioscience,
San Diego, CA), and PE-labeled IL-22 (R&D Systems, Abing-
don, UK), cells were first fixed in 4% paraformaldehyde
(Sigma) in phosphate buffered saline and permeabilized in
0.1% saponin (Sigma); antibodies and wash buffer for intra-
Figure 1. Enrichment of interleukin-17 (IL-17)–positive, CD4 T cells in synovial fluid from
patients with juvenile idiopathic arthritis (JIA) and correlation with clinical subtype. A, Represen-
tative dot plots of paired samples of peripheral blood mononuclear cells (PBMCs) and synovial
fluid mononuclear cells (SFMCs) from a patient with JIA. Cells were stained for surface expression
of CD3 and CD4 and then for intracellular expression of IL-17 and were analyzed by flow
cytometry, gated on live lymphocytes and CD3 cells. Numbers in each compartment are the
percentage of cells. B, Numbers of IL-17 cells as a percentage of CD4 T cells in SFMCs from
JIA patients (n  28), PBMCs from JIA patients (n  22), and PBMCs from healthy controls (n 
9). Bars show the median. C, Numbers of IL-17 cells as a percentage of CD4 T cells in PBMCs
(PB) and SFMCs (SF) from patients with persistent (n  9 PBMC samples; n  12 SFMC samples)
and extended (n  6 PBMC samples; n  13 SFMC samples) oligoarticular JIA (O-JIA) and in
PBMCs from healthy controls (n  9). Bars show the median.
IL-17–PRODUCING T CELLS IN JUVENILE ARTHRITIS 877cellular staining also contained 0.1% saponin. Staining with
allophycocyanin-labeled anti-FoxP3 was performed according
to the manufacturer’s instructions (eBioscience).
Flow cytometric data were collected with a Cyan ADP
flow cytometer (Dako); 100,000 to 200,000 events were col-
lected for each condition, and cells were gated by their light
scatter properties. Data were analyzed using FlowJo software
(Tree Star, Ashland, OR).
Immunohistochemical staining of synovial tissue.
Cryosections (7) were cut, fixed in acetone, and stained by
standard immunohistochemistry methods using goat anti-
human IL-22 (Santa Cruz Biotechnology, Santa Cruz, CA),
goat anti-human IL-17 (R&D Systems), mouse anti-human
CD4 (Novocastra, Newcastle upon Tyne, UK), isotype control
antibody (Dako), or no primary antibody control, followed by
biotinylated rabbit anti-goat Ig (Dako) or biotinylated donkey
anti-mouse Ig (Chemicon, Billerica, MA) and a standard
avidin–biotin complex protocol.
Chemotaxis assay. Assays for chemotaxis to CCL20
(Insight Biotechnology, Wembley, UK) were performed using
5-m–pore polycarbonate filters in a Transwell chamber
(Corning Life Sciences, Schiphol-Rijk, The Netherlands) as
described elsewhere (34), with a range of 10–1,000 ng/ml of
CCL20 in RPMI 1640–0.5% bovine serum albumin (BSA).
After 90 minutes, migrated cells were recovered, stimulated
with PMA and ionomycin in the presence of Brefeldin A, and
stained with anti-human IL-17, IFN, CD3, and CD4 as
detailed above. Immediately prior to acquisition of data by
flow cytometry, 20,000 fluorescence-activated cell sorter count-
ing beads (Perfect Count; Cytognos, Salamanca, Spain) were
added per sample. The number of cells acquired was standard-
ized relative to the number of beads. To calculate the chemo-
tactic index, the number of cells that migrated in response to
chemokine was divided by the number of cells that migrated
spontaneously to control medium (RPMI–0.5% BSA).
Statistical analysis. Data were analyzed using SPSS
v14.0 software (Chicago, IL) and GraphPad Prism software
(San Diego, CA). Comparison of IL-17 cell numbers be-
tween groups was analyzed by the Mann-Whitney U test.
Linear regression was used to assess the relationship between
IL-17 cells and Treg cells. For this comparison, skewed data
were log-transformed before analysis.
RESULTS
Enumeration of IL-17–producing T cells in the
blood and joints of patients with JIA and correlations
with clinical phenotype. We analyzed by flow cytometry
mononuclear cells derived from peripheral blood and
synovial fluid obtained from children with JIA for the
presence of IL-17–producing T cells. We found a clear
enrichment of IL-17–producing T cells within the syno-
vial fluid as compared with the peripheral blood of the
JIA patients (Figure 1). The majority of IL-17 T cells
were within the CD4,CD3 population (Figure 1A).
In PBMCs from JIA patients, the median number of
IL-17–producing cells constituted 0.43% of the CD4 T
cell population (interquartile range [IQR] 0.3–0.9). This
did not differ significantly from the IL-17 T cell
numbers in PBMCs from healthy controls (median
0.67%; IQR 0.5–0.8) (Figure 1B). In contrast, the num-
ber of IL-17,CD4 T cells in SFMCs was significantly
increased (median 1.2%; IQR 0.7–2.6) as compared with
that in PBMCs from both the JIA patients (P  0.0001)
and the controls (P  0.018) (Figure 1B). Although this
difference was seen across all subtypes of JIA, the degree
of enrichment varied between clinical phenotypes.
Figure 2. Characterization of interleukin-17 (IL-17)–positive T cells
in patients with juvenile idiopathic arthritis (JIA). Peripheral blood
mononuclear cells (PBMCs) and synovial fluid mononuclear cells
(SFMCs) from JIA patients were analyzed by flow cytometry. A and B,
Representative dot plots of paired PBMCs and SFMCs stained for
CD3, IL-17, and T cell receptor / (TCR/)( A) as well as for CD3,
IL-17, and CD8 (B), both gated on live lymphocytes and CD3 cells.
C, Representative dot plot of JIA SFMCs stained for CD3, CD4,
CD45RO, and IL-17 gated on live lymphocytes, CD3 cells, and CD4
cells. Numbers in each compartment are the percentage of cells.
878 NISTALA ET ALFigure 3. Inverse relationship between the number of synovial forkhead box P3 (FoxP3)–positive
regulatory T cells and interleukin-17 (IL-17)–positive, CD4 T cells. A, Representative dot plots
of paired samples of peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear
cells (SFMCs) from a patient with juvenile idiopathic arthritis (JIA) and of samples of PBMCs from
a healthy control subject. Cells were stained for surface expression of CD3, CD4, and CD25 and
then for intracellular expression of FoxP3 and were analyzed by flow cytometry, gated on live
lymphocytes and CD3,CD4 cells. Numbers in each compartment are the percentage of cells. B,
Numbers of FoxP3 cells as a percentage of CD4 T cells in PBMCs and SFMCs from patients
with persistent (n  8) and extended (n  5) oligoarticular JIA (O-JIA) and in PBMCs from 6
healthy controls. Bars show the median. C, Comparison of the numbers of IL-17 and FoxP3
cells as percentages of CD4 T cells in SFMCs from 15 JIA patients. Linear regression was
performed on log-transformed data.
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by subtype revealed a relationship to disease severity.
There was a significant enrichment of IL-17 T cells in
the joints of children with extended oligoarticular JIA,
the more severe form of JIA (median 2.1; IQR 1.3–4.8),
as compared with persistent oligoarticular JIA, the
milder form of the disease, which is self-remitting (me-
dian 0.91; IQR 0.6–2.8 [P  0.046]) (Figure 1C).
No IL-17–producing cells were demonstrated in
the TCR/ population, and few CD8 T cells were
found to be IL-17 in either the JIA patients or the
controls (Figures 2A and B). Consistent with the dem-
onstration that IL-17 T cells reside within the memory
pool (27,35), IL-17,CD4 cells from both compart-
ments (peripheral blood and joint) all expressed
CD45RO (Figure 2C).
Figure 4. Divergent patterns of chemokine receptor CCR4 expression of interleukin-17 (IL-17)–
positive, CD4 T cells in peripheral blood mononuclear cells (PBMCs) and synovial fluid
mononuclear cells (SFMCs) from patients with juvenile idiopathic arthritis (JIA). A, Representa-
tive dot plots of paired PBMCs and SFMCs from JIA patients, showing CCR6 and CCR4
expression on IL-17,CD4 T cells. Cells were analyzed by flow cytometry, gated on live
lymphocytes and CD4 cells. Numbers in each compartment are the percentage of cells. Results
are representative of 1 experiment of 5 experiments performed. B, Percentage of all CD4 T cells
and IL-17,CD4 T cells expressing CCR6 and CCR4 in the peripheral blood and synovial fluid
of 5 patients with JIA. Values are the mean and SEM.
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T cells in patients with JIA. Since it is known that the
numbers of Treg cells in the joint also correlate with
different clinical phenotypes of JIA (31,32), we next
examined the relationship between Treg cells and Th17
cells in the context of this autoimmune disease. Pre-
vious studies using high levels of surface expression of
CD25 to identify Treg cells showed that these cells
expressed high levels of messenger RNA for the FoxP3
transcription factor and confirmed their suppressive
function in vitro (31). In the present study, we used
protein expression of FoxP3 as analyzed by flow cy-
tometry to identify Treg cells. We confirmed that in the
joint, where many T cells are highly activated, not all
CD25
bright cells coexpressed FoxP3, while some FoxP3
cells resided in the CD25
dim or CD25– population
(Figure 3A).
Using FoxP3 protein expression to identify
synovial Treg cells in samples from patients with dif-
ferent clinical subtypes of JIA, we confirmed our previ-
ous findings of a significant difference in the number
of Treg cells in the joints of patients with persistent
oligoarticular JIA and those with extended oligoartic-
ular JIA (P  0.018) (Figure 3B). Remarkably, the
simultaneous analysis for IL-17,CD4 T cells and
FoxP3 Treg cells showed that these 2 populations
exist in an inverse relationship at the site of inflam-
mation (P  0.016) (Figure 3C). No analogous relation-
ship was observed in PBMCs from either the patients
or the controls, and no cells expressed both FoxP3 and
IL-17.
Chemokine receptor analysis of IL-17 T cells
from patients with JIA. We next considered the chemo-
tactic influences that could affect the recruitment of
IL-17 T cells to sites of inflammation. We have pre-
viously shown high levels of expression of the chemokine
receptors CCR5 and CXCR3 on synovial T cells in JIA
(3). Recently reported data suggest that human Th17
cells express CCR6 and CCR4, but that a population of
cells that produce both IFN and IL-17 preferentially
expresses CCR6 and CXCR3 (27). We therefore inves-
tigated the expression of these receptors on Th17 cells in
JIA. Analysis of the expression of CCR6 confirmed that
a high proportion of IL-17–producing T cells from both
the peripheral blood and joint expressed CCR6, as
compared with the CD4 T cell population as a whole
(Figures 4A and B). In contrast, IL-17 T cells from the
joint expressed lower levels of CCR4 than did their
counterparts (IL-17,CD4 T cells) from the blood
(Figures 4A and B). Interestingly, FoxP3 Treg cells in
the JIA joint also expressed high levels of both CCR4
(31) and CCR6 (data not shown).
Coexpression of inflammatory cytokines by IL-
17,CD4 T cells from synovial fluid and synovial
tissue obtained from patients with JIA. Given the ap-
parent discrepancy in the expression of CCR4 on IL-
17 synovial T cells compared with that on IL-17
peripheral blood T cells and the recent demonstration
that cells with a CCR6,CCR4– phenotype may include
Th1 cells that also produce IL-17, we hypothesized that
synovial IL-17 T cells in JIA would include a popula-
tion of cells that secrete both IL-17 and IFN.W e
therefore investigated the functional diversity of these
cells.
IL-22 has been demonstrated to be produced by
Th17 cells (36,37) and has been implicated in RA (38).
Analysis of IL-22 and IFN production in IL-17,
CD4 T cells showed that a significant proportion of
cells that produced IL-17 also produced IL-22 and
similarly demonstrated coexpression of IL-17 and IFN
(Figure 5A). The number of these “double cytokine
(IL-17 and IFN)–positive” T cells were consistently
higher in SFMC T cells than in PBMC T cells from
either the patients or the controls. Thus, IL-17 and IFN
double-positive CD4 T cells constituted a median of
46.8% (IQR 26.3–59.1) of IL-17–producing cells in the
joint (n  14), as compared with a median of 12.0%
(IQR 4.4–15.5) in control PBMCs (n  9) and 16.1%
(IQR 8.7–23.9) in JIA PBMCs (n  14), both of which
were significantly different from the median in SFMCs
(P  0.001 for each comparison). In contrast, production
of the Th2 cytokine IL-4 was mutually exclusive with
IL-17, with expression of these cytokines in discrete and
separate populations in both the blood and the joint
(n  5) (Figure 5A).
To demonstrate the expression of both IL-17
and IL-22 at the site of disease, synovial tissue was
analyzed by immunohistochemistry. This analysis con-
firmed that both IL-17 and IL-22 were expressed on
infiltrating CD4 cells within the inflamed synovial
tissue (Figure 5B).
Functional migration of Th17 cells to CCL20.
The ability of CD4 T cells from PBMCs to migrate in
response to the CCR6 ligand CCL20 was tested using
standard migration assays. Migrated cells were then
assayed for the production of IL-17 and IFN as de-
IL-17–PRODUCING T CELLS IN JUVENILE ARTHRITIS 881Figure 5. Dysregulated cytokine expression by interleukin-17 (IL-17)–positive, CD4 T cells in
the synovial fluid of juvenile idiopathic arthritis (JIA) patients. A, Representative dot plots of
paired samples of peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear
cells (SFMCs) from patients with JIA. Cells were stained for intracellular cytokines IL-17,
interferon- (IFN), IL-22, and IL-4 and analyzed by flow cytometry, gated on live lymphocytes
and CD3,CD4 cells. Numbers in each compartment are the percentage of cells. B, Immuno-
histologic localization of IL-17 and IL-22 in JIA synovial tissue. Frozen sections of synovial biopsy
tissue were stained for CD4, IL-17, and IL-22 by standard immunohistochemical techniques. Tissue
sections show typical hypertrophied synovium and dense inflammatory infiltrate. Positive cells
expressing the marker of interest are stained brown; arrow shows typical positive cells. Bar  20
m.
882 NISTALA ET ALscribed above (Figure 6). IL-17 T cells from both the
patients and the controls were enriched in cells that
migrated toward CCL20 (Figure 6A) and, as expected,
the response titrated across a range of concentrations
(Figure 6B). Under standard conditions using 100 ng/ml
of CCL20 ligand, the mean chemotactic index for IL-
17,CD4 T cells from PBMCs did not differ signifi-
cantly between healthy controls (mean  SD 3.2  2.3)
and JIA patients (3.8  0.9).
DISCUSSION
In this report, we present the first detailed ana-
lysis of IL-17–producing T cells in JIA and their rela-
tionship to FoxP3 regulatory T cells. Multiple proin-
flammatory mediators contribute to the tissue damage
seen in inflammatory arthritis in humans, both in adults
and in children. These include TNF, IL-1, IL-6,
RANKL, and chemokines, many of which have been
Figure 6. Preferential migration of interleukin-17 (IL-17)–positive, CD4 T cells to the CCR6
ligand CCL20 as compared with CD4 T cells. Purified CD4 T cells from patients with juvenile
idiopathic arthritis (JIA) and healthy controls were migrated to 10 ng/ml, 100 ng/ml, or 1,000 ng/ml
of CCL20 or RPMI 1640–0.5% bovine serum albumin (BSA). A, Cells from healthy controls
analyzed by intracellular cytokine staining for IL-17 and interferon- (IFN) before (left) and after
migration to control medium (RPMI 1640–0.5% BSA) (middle) or 1,000 ng/ml of CCL20 (right).
Cells were analyzed by flow cytometry, gated on live CD3,CD4 cells. Numbers in each
compartment are the percentage of cells. Results are representative of 1 experiment of 5
experiments performed. B, Response of IL-17,CD4 T cells and all CD4 T cells to a titration
of the CCL20 gradient. Data are expressed as the chemotactic index (ratio of cells migrating to
CCL20 divided by cells migrating to control medium). Values are the mean  SEM of 5
experiments.
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both RA and JIA patients (39,40). It is now well
established that inflammatory reactions may “coexist”
with a regulatory response. We propose that, at least in
JIA, the balance between proinflammatory factors and
immune regulation has a profound impact on clinical
phenotype. Thus, in patients with the mild, remitting
phenotype of JIA known as persistent oligoarticular JIA,
we and other investigators have previously seen that
Treg cells are present at higher numbers in the inflamed
joint than in patients with more severe disease (31,32).
We have now extended these findings by our analysis of
IL-17–producing T cells in JIA.
Despite the success of treatment of childhood
arthritis with TNF blockade, a proportion of children
with JIA fail to achieve remission with standard thera-
pies. There is renewed interest in novel targets for
therapeutic blockade in arthritis, including IL-17 family
members, which both synergize with, and have effects
independent of, TNF and IL-1 (41), as well as IL-17
receptors (42,43). IL-17 has been demonstrated in the
joints of patients with RA and patients with JIA, but to
date, few studies have characterized the cells that pro-
duce IL-17 in humans with arthritis. In animal model
systems, including collagen-induced arthritis, IL-17 has
been shown to be critical and sufficient to produce
disease in the absence of IFN (44), and several reports
suggest that IFN can even be protective, perhaps by
inhibiting the development of Th17 cells (35,45). Initial
reports suggest that T cells that secrete IL-17 can be
detected in the peripheral blood of healthy donors and
may reside in more than 1 subpopulation (27), which
may be distinguished by their differential expression of
specific chemokine receptors. It is now vital to have a
detailed analysis of IL-17–producing T cells in human
disease in order to better understand their role in
disease pathogenesis and to design appropriately tar-
geted therapies.
In this study of 36 children with JIA, we showed
that T cells that produce IL-17 are highly enriched
within the inflamed joints of our patients, and we
demonstrated these cells at the site of disease within the
joint. IL-17 was produced predominantly by CD4 T
cells in the joint, and these cells were present at signif-
icantly higher numbers in the joint than in either the
paired blood samples from JIA patients or the blood of
healthy controls. The IL-17 T cells were uniformly
within the memory CD4,CD45RO population. Pre-
viously, IL-17 was estimated by staining studies to be
produced by 1% of synovial tissue T cells. Our flow
cytometric data from synovial fluid T cell analyses are
consistent with this estimate.
We also demonstrated that these IL-17 cells
were present in higher numbers in the joints of patients
with extended oligoarticular JIA, the more severe phe-
notype, than in those with persistent oligoarticular JIA,
the mild form of disease. These results suggest that
IL-17 T cells relate directly to clinical phenotype in
JIA. Given previous findings on the role of Treg cells in
JIA and evidence that Treg cells and Th17 cells may
share developmental pathways, we also analyzed Treg
cell numbers in these patients and found a reciprocal
relationship between Treg cell and IL-17 T cell num-
bers in the joint. This suggests that within the micro-
environment of the joint, an integrated set of factors that
lead to the recruitment or survival of these 2 T cell
populations will lead to a predominance of either Treg
cells or IL-17 T cells.
Several studies have demonstrated that the de-
velopment of murine Th17 cells and Treg cells may be
interrelated, both being dependent on TGF, yet recip-
rocally influenced by cytokines, such as IL-6, IL-1 (which
switch toward Th17) (8), as well as IL-2 and the vitamin
A metabolite all-trans-retinoic acid, both of which switch
toward Treg cells (46,47). However, the majority of
published studies were performed using highly purified
naive T cells, and the data are not readily extrapolated to
apply to sites of chronic inflammation in human disease.
Findings of a recent study suggest that Treg cells them-
selves may convert to Th17 cells in the presence of IL-6
(48). It is known that Treg cells can themselves limit
expansion of Th17 cells, both in vitro (12) and in vivo
(45). Analyses of IL-1, IL-6, and IL-2 at sites of tissue
inflammation will clearly be of importance. Our prelim-
inary data (Nistala K, Moncrieffe H: unpublished obser-
vations) suggest that there is a correlation between the
levels of IL-6 and the levels of IL-17 within the joint.
Emerging data in human studies suggest that the “rules”
governing human Th17 cells may diverge from those that
govern mouse data; for example, in humans, Th17 cell
generation appears to be driven by IL-6 or IL-1, but
not TGF, and IL-2 fails to inhibit Th17 cell generation
(35). The reciprocal effects of all-trans-retinoic acid on
the development of Th17 and Treg cells have yet to be
tested in humans.
It has previously been shown that RA synovial
fluid T cells may coexpress IFN and IL-17 (49). T cell
clones grown from the joint may produce both IFN and
IL-17 (50), although these cells were not fully character-
ized ex vivo. In patients with Lyme arthritis, IL-17 T
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and TNF populations of CD4 T cells (29). Evi-
dence showing that human Th17 cells typically express
CCR4 and CCR6 and that these are enriched in memory
cells specific for fungal antigens, such as Candida albi-
cans, whereas a fraction of Th1 cells that produce both
IFN and IL-17 typically express CCR6 and CXCR3,
has been reported (27). In our study, we confirmed that
in the synovial fluid of JIA patients and in the blood of
both JIA patients and controls, the majority of IL-17 T
cells express CCR6. Migration of CD4 T cells toward
a CCL20 gradient demonstrated an enrichment of IL-
17 T cells in both patients and controls.
Interestingly, the CCR6 ligand CCL20 (previ-
ously called macrophage inflammatory protein 3)i s
itself produced by synovial explants in response to IL-17
(51). In addition, CCL20 has been shown to be up-
regulated in human Th17 cells and, in fact, to be a
defining feature of the Th17 “signature,” along with
IL-17 and IL-22 (14). The high levels of this chemokine
in the synovial fluid of patients with arthritis may
contribute to the enrichment of IL-17–producing cells
within the joint (52). Our data raise the possibility that
Th17 cell migration to the joint may set up a positive
feedback loop for further recruitment through the au-
tologous production of CCL20.
In PBMCs, the expression of CCR4 on IL-17 T
cells mirrored that of CCR6. However, within the joint,
IL-17 T cells had a variable expression of CCR4.
These data suggested that a CCR6,CCR4– population
was enriched within the inflamed joint and led us to
further characterize other cytokines produced by these
cells. IL-17 T cells in peripheral blood were clearly
distinct from either Th1 cells (defined by IFN produc-
tion) or Th2 cells (defined by IL-4 production). How-
ever, again, the site of inflammation showed a dysregu-
lation, in that typically, more than half of those T cells
producing IL-17 were within the IFN-producing popu-
lation. The small IL-4 population of T cells within the
joint was distinct from the IL-17 cells. We have
previously shown that Th1,IFN,CXCR3,CD4 T
cells are highly enriched in the synovium in JIA (3). The
findings of our current study suggest that within this
proinflammatory population, a proportion of these cells
also make the highly active cytokine IL-17.
This study is the first to demonstrate that IL-17–
expressing T cells are highly enriched in the inflamed
joints of children with arthritis and that their numbers
directly correlate with the clinical phenotype. These
IL-17 T cells include populations that also produce
IL-22 and IFN, but not IL-4. The synovial IL-17 T
cells all express CCR6, but have a variable expression of
CCR4. We propose that despite the highly enriched
numbers of IL-17 T cells in the joint compared with
the blood, immune regulation also has a direct impact at
sites of inflammation in childhood arthritis, since we
found a reciprocal relationship between IL-17 T cells
and FoxP3 Treg cells. This suggests an explanation for
the persistence of arthritic damage to the joint despite
the presence of regulation. The elucidation of factors
that control this balance and reciprocal relationship is
crucial to our understanding of ongoing autoimmune
pathology in arthritis and, therefore, to our ability to
intervene therapeutically in favor of regulation.
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Errata
DOI 10.1002/art.23420
In the article by Sanchez et al published in the February 2008 issue of Arthritis & Rheumatism (pages
442–455), the last name of the third author was misspelled in the byline. The correct spelling is Bellahce `ne.
DOI 10.1002/art.23421
In the article by Olivotto et al published in the January 2008 issue of Arthritis & Rheumatism (pages 227–239),
the institutional affiliations of two of the authors were reported incompletely. The affiliation of Dr. Marianna
Penzo should have been listed as Vita-Salute San Raffaele University, Milan, Italy, Centro Ricerca Biomedica
Applicata (CRBA), Policlinico S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy,
and Biochemistry and Cell Biology Department, Stony Brook University, Stony Brook, New York; and that of
Dr. Kenneth B. Marcu should have been listed as CRBA, Policlinico S. Orsola-Malpighi University Hospital,
University of Bologna, Bologna, Italy, and Biochemistry and Cell Biology Department, Stony Brook
University, Stony Brook, New York.
DOI 10.1002/art.23422
In the article by Maini et al published in the September 2006 issue of Arthritis & Rheumatism (pages
2817–2829), there was an error in one of the headings in Table 1. The heading “Duration of RA, months”
should have read “Duration of RA, years.”
We regret the errors.
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